|
GENOUS™ SUCCESS STORY
Overcoming Adversity: A Young Woman's Battle with Breast and Lung Cancer
CHALLENGE
The patient's health deteriorated rapidly (ECOG score was 3), making the need for treatments that could target multiple cancers at once more urgent than ever.
The 33-year-old woman's life was turned upside down after she was diagnosed with HER2-positive breast cancer. Despite aggressive treatments, including Herceptin and chemotherapy, the cancer persisted. She was later diagnosed with lung cancer and brain metastases.
PRECISION CANCER SOLUTIONS
Determined to find a solution, her team turned to precision oncology, and they chose the services of Genomate. Next-generation sequencing of 591 cancer genes was performed, based on the liquid biopsy. The results revealed activating mutations in EGFR and TP53 (confirmed to be germline). Together, Genomate processed these findings and provided a ranked list of potential therapies, tailored to the patient’s specific genetic profile. The molecular oncology panel reviewed the report and selected Afatinib—an inhibitor of both EGFR and HER2—as the treatment best suited to the patient’s complex situation.
THE RIGHT DRUG. THE FIRST TIME. EVERYTIME
The patient’s response to Afatinib was rapid. The tumor shrank and the patient returned to normal physical condition (ECOG score was 0). Follow-up showed no tumor for six months, before the patient switched to Osimertinib, and the condition continued to be effectively controlled.
For the treatment team, this means:
Higher success rate
Make decisions faster
Limit guesswork and side effects
Give patients the best treatment opportunities
OUTCOMES AND IMPACT OF TARGETED THERAPY
